Skip to content

Earnings call

Jagsonpal Pharmaceuticals Q4 FY26 earnings call: Jagsonpal Pharmaceuticals Limited's objective is to beat Indian Pharma Market growth, with an aspiration to beat it by 1.5x

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Objective is to beat Indian Pharma Market growth, with an aspiration to beat it by 1.5x. The company revenue grew around 7% in FY26, while net profit grew 19% before exceptional items. 92% of Jagsonpal Pharmaceuticals Limited’s portfolio is outside the NLEM, which is price control, and almost 90% of its portfolio can have a price increase of up to 9.9%. Top 10 brands constitute approximately 58% to 60% of its total sales, depending on the quarter, and nine of those brands rank within the top five in their respective categories. The company had a cash position upwards of INR190 crores at the end of FY26, or on 31st March.

The numbers management gave

Results

  • The company revenue grew around 7% in FY26, while net profit grew 19% before exceptional items.
    Show source
    For FY26, while the revenue growth has been modest at around 7%, our net profit has grown at 19% before exceptional items.
  • EBITDA grew 9% year-on-year to close to INR11 crores in Q4 FY26, with stable margins at close to 16%, reflecting disciplined cost management and operating resilience.
    Show source
    This translated into EBITDA growth of 9% year-on-year to close to INR11 crores, while maintaining stable margins at close to 16%, reflecting disciplined cost management and operating resilience.
  • PAT rose 31% year-on-year to close to INR9 crores in Q4 FY26, and its PAT margin expanded to approximately 14%.
    Show source
    Profitability saw a sharper uptick with PAT rising to 31% year-on-year to close to INR9 crores and with a PAT margin expanding to approx. 14%.
  • The company revenue grew approximately 7% to INR287 crores in FY26, and operating EBITDA stood at close to INR61 crores with a margin of approximately 21%.
    Show source
    For the full year, FY26 revenue grew by approx. 7% to INR287 crores and operating EBITDA stood at close to INR61 crores with the margin of approx. 21%.
  • The company profits from operations grew 19% year-on-year to close to INR45 crores in FY26, reflecting a margin of approximately 16%.
    Show source
    At the profitability level, our profits from operations grew by 19% year- on-year to close to INR45 crores, reflecting a margin of approx. 16%.
  • Net working capital cycle was close to 11 days in Q4 FY26.
    Show source
    Working capital remains well-managed with net working capital cycle at close to 11 days, reflecting our continued focus on financial discipline and prudent capital allocation.
Show 17 more statements

Results

  • Gross margin for the full year was approximately 64.2%, with a minor change of about 20-30 bps due to product mix.
    Show source
    Because our full year gross margins are largely in line, there has been minor change, but it is more or less 64.2%.
  • Growth contribution from new products is 3% plus.
    Show source
    So we are already at 3% plus in terms of our growth contribution from the new products.
  • The company reported volume growth of 2%.
    Show source
    Now for Jagsonpal, the numbers reported are volume growth is 2%.
  • New product growth was 3.2%, price growth was in the range of 6% to 7%, and total growth was 12%.
    Show source
    Sum total of this comes to 12%.
  • Growth on its top 10 brands was in line with the rest of its portfolio, with hardly a 1% change.
    Show source
    So top 10 brands are obviously constituting much more healthier bottom line for us, so our growth on those brands has been in line with the rest of the portfolio.
  • Revenue grew 10% year-on-year to INR150 crores in H1 FY26.
    Show source
    So from a financial perspective, Q4 FY26 reflects a strong improvement in operating performance, with revenue growing by 10% year-on- year to INR64 crores, supported by healthy demand momentum across key therapies and stronger execution.
  • Gross margins in the business are about 65%, if not more.
    Show source
    Having said that, I believe pharmaceutical industry overall will be lesser impacted given that the gross margins in this industry are better than most other industries.
  • The company returned to growth in Q4 FY26 after two quarters of sluggish performance, supported by sharpened execution focus, especially on MR productivity and retention.
    Show source
    I am pleased to report that Jagsonpal is back on growth in Q4 after two quarters of sluggish performance.
  • Growth was led by traction across Gynaecology and Dermatology, where prescription momentum remained an important growth anchor; growth in these segments more than offset moderation in a few mature brands in select therapies during the year.
    Show source
    Growth has been led by strong traction across the key therapies, in particularly Gynaecology and Dermatology.
  • The impact of the new labor code was Jagsonpal Pharmaceuticals Limited's only exceptional item during FY26 and was taken in Q3.
    Show source
    The only exceptional item during the year was the impact of new labor code, which was taken in Q3, and overall the business continues to show meaningful improvement in core quality and profitability.

Money and capital

  • The company had a cash position upwards of INR190 crores at the end of FY26, or on 31st March.
    Show source
    The performance is underpinned by financial discipline and focused execution, which is also reflected in our strong cash position, which was upwards of INR190 crores at the end of the year or on 31st March.
  • The board of Jagsonpal Pharmaceuticals Limited recommended a 200% dividend for FY26, including a one-time special dividend of 75%, subject to shareholder approval at the forthcoming AGM.
    Show source
    Alongside the INR40 crores buyback announced on 12th March at INR250 per share with no promoter participation, the board has also recommended a 200% dividend for the year, which includes a one-time special dividend of 75%.
  • The company had a cash position of over INR190 crores in Q4 FY26.
    Show source
    We also continue to maintain a strong balance sheet with a cash position of over INR190 crores.
  • The company received shareholders' approval for the proposed INR40 crores buyback of up to 16 lakh equity shares at INR250 per share; the promoters shall not participate.
    Show source
    On the buyback front, we have received shareholders' approval for the proposed INR40 crores buyback of up to 16 lakh equity shares at a price of INR250 per share.
  • The company expects its ROE to increase from approximately 16% to 18% and its ROCE to improve from approximately 22% to close to 26% as a result of the buyback.
    Show source
    This move is expected to have significant impact on our return ratios, with ROE increasing from approx. 16% to 18%, while ROCE shall improve from approx. 22% to close to 26%.
  • The company shall return over INR66 crores to shareholders between the buyback and dividend.
    Show source
    Between buyback and dividend, the company shall be returning over INR66 crores to the shareholders.
  • The company can raise upwards of INR200 crores as fresh debt and has close to INR190 crores of cash; based on its cash flows, it is hopeful of recouping its buyback and dividend outlay within the next 12 months.
    Show source
    So if you look at our own balance sheet, you can easily believe that we can raise upwards of INR200 crores as fresh debt in the company.

What it expects ahead

What management expects

  • Objective is to beat Indian Pharma Market growth, with an aspiration to beat it by 1.5x.
    Show source
    And that is what our objective has been and obviously we are taking aspiration to beat it by 1.5x, which is 1.5 times more than the Indian Pharma Market growth.
  • The company intends to have approximately 9 to 10 new product launches in the current year, half of which will rejuvenate older legacy brands.
    Show source
    We intend to have similar number approximately 9 to 10 in this current year as well, in which half of it will be more of rejuvenating the older brands, the legacy brands that we have.
  • The company is targeting growth at 1.5x the pharma industry growth, which currently translates to 12% to 15%.
    Show source
    And if I calculate 1.5x of that, it translates to anywhere between 12% to 15% right now.
  • The company expects close to around five or six opportunities in new product therapies.
    Show source
    And there will be close to around five or six opportunities which will be in the new product therapies.
  • The company does not expect the cost impact to have a significant impact on the company’s profitability.
    Show source
    I don't believe so.
  • Growth will be entirely driven by productivity improvement, with no current intention to increase MR or manager numbers.
    Show source
    However, I can promise you one thing that the growth will be entirely driven with the productivity improvement as we don't intend to increase the MR numbers currently or managers number currently.

What it is building and selling

Demand and pricing

  • 92% of Jagsonpal Pharmaceuticals Limited’s portfolio is outside the NLEM, which is price control, and almost 90% of its portfolio can have a price increase of up to 9.9%.
    Show source
    So almost you can say 90% of my portfolio I can go up to a price increase of 9.9%.
  • Indian Pharma Market volume growth was approximately 1%, new product growth was around 3.1%, price growth was around 4.8%, and total growth was around 8.5%, or 9% rounded off.
    Show source
    So sum total of this is around 8.5%.
  • The Middle East situation has had no impact on demand for Jagsonpal Pharmaceuticals Limited’s business.
    Show source
    Clearly from a demand perspective, there is no impact of whatever is happening on the Middle East.
  • The pharma market is expected to perform better as launches in metabolic and anti-obesity increase. Replaced by a later filing.
    Show source
    I'm repeating the word and underlining this word, expected to perform better.

Segments

  • Top 10 brands constitute approximately 58% to 60% of its total sales, depending on the quarter, and nine of those brands rank within the top five in their respective categories.
    Show source
    Our top 10 brands currently constitute approximately 58% to 60% of our total sales, depending on the quarter, providing both the scale and stability for the business.
  • The company had six new product launches and three brand-extension SKUs.
    Show source
    Amrut Medhekar: So we had total of six new product launches and three SKUs, I mean the brand extensions.
Show 1 more statement

Segments

  • New product establishment can take a year plus for prescriptions to start flowing in from each pin code of the country.
    Show source
    New product establishment is a very, very hard work for prescriptions to start flowing in from each and every pin code of the country, which will take possibly a year plus for us to do that.

Risks, rules and outside factors

Outside factors

  • Vendors are seeing cost increases, especially for packaging material, and will look to pass on some increases as their inventories are carried.
    Show source
    Clearly all the vendors are seeing cost increases and they obviously while they are carrying certain inventories, they will be looking to pass on some of the cost increases.

Everything else said on the call

What management stressed

  • Strategic priorities include driving organic growth through enhanced MR productivity, sharper brand focus and disciplined cost management, while evaluating value-accretive inorganic opportunities. Replaced by a later filing.
    Show source
    Page 2 of 17 Jagsonpal Pharmaceuticals Limited April 28, 2026 Looking ahead, our strategic priorities remain consistent, which is about driving organic growth through enhanced MR productivity, sharper brand focus, and disciplined cost management, while we continue to evaluate value-accretive inorganic opportunities.

Group structure

  • The company has the wherewithal to undertake an acquisition of up to INR400 crores with its own balance sheet.
    Show source
    So technically we do have wherewithal to undertake an acquisition of up to INR400 crores with our own balance sheet.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Anupam Agarwal: Yes, thank you so much for taking my question and congratulations on good numbers, sir. My first question is that if you can break down your full year growth of 12.2% as per Pharmarack between the four therapy segments, that will be really helpful.

    Answer, amrut medhekar

    Amrut Medhekar: Therapy-wise we are overweight on three therapies, which is Gynaec, Ortho, and Dermatology. Currently offhand I won't be able to give you exact breakup between these three therapies.

    Answer, manish gupta

    Manish Gupta: Yes, but I'll give you, mean, while we don't have latest numbers, but roughly about half of our business is Gynaecology, 25% odd would be Ortho, and another 10% to 15% will be Derma.

    Answer, amrut medhekar

    Amrut Medhekar: So largely driven by number one, Gynaec and number two is Derma.

    Answer, derma agarwal

    Anupam Agarwal: Okay. Sir, you've talked about MR productivity, just a question on that. So what is the MR count today and what was the productivity let's say, same quarter last year and what was it in the fourth quarter?

    Answer, amrut medhekar

    Amrut Medhekar: So number of MRs continue to be same, there is no new addition of MR in the last quarter, which is under reference now. And productivity, the growth that you are looking at is pure play, productivity improvement by the existing MRs. Anupam Agarwal: Understood.

  2. Question

    Sir, in your presentation there are a couple of lines mentioned about you launching or ideating one to two products every quarter. How are we placed on that? What is the kind of new product launches that we've done in the fourth quarter? What was it in the last full year and what are we planning for the next year?

    Answer, amrut medhekar

    Amrut Medhekar: So we had total of six new product launches and three SKUs, I mean the brand extensions. We intend to have similar number approximately 9 to 10 in this current year as well, in which half of it will be more of rejuvenating the older brands, the legacy brands that we have. So some Page 7 of 17 Jagsonpal Pharmaceuticals Limited April 28, 2026 brand extension in the same legacy brands. And there will be close to around five or six opportunities which will be in the new product therapies.

  3. Question

    Anupam Agarwal: New product therapies or new products within the existing therapies?

    Answer, amrut medhekar

    Amrut Medhekar: New products within the same therapies, our strength areas which is Gynaec, Ortho, and Derma.

    Answer, derma agarwal

    Anupam Agarwal: Understood. Great sir, I just wanted your breakup of the growth therapy-wise, so maybe I'll take that offline. That's it from my side. Thank you so much.

  4. Question

    Gautami Agarwal: So, my first question is on the gross margin side. As we can see Q-o-Q this year the gross margins have declined and on the other hand the other expenses have increased Q-o-Q and Y-o-Y. So is there a particular factor or is it fair to assume that these are the stable numbers going ahead?

    Answer, manish gupta

    Manish Gupta: You're referring to any specific number of Quarter 4 or...

  5. Question

    Gautami Agarwal: Quarter 4, sir.

    Answer, manish gupta

    Manish Gupta: No, so, are you referring to Quarter 4 or for the full year? Because our full year gross margins are largely in line, there has been minor change, but it is more or less 64.2%. Yes, about 20-30 bps, which is just a product mix issue, nothing more than that.

  6. Question

    Gautami Agarwal: All right, sir. And what about the other expenses part?

    Answer, manish gupta

    Manish Gupta: Other expenses also if you look at that has marginally increased, I mean 30 bps, that could be attributable to largely these are a bit of timing issue. Let me just give you example like when do you conduct your cycle meeting, your annual cycle meeting, budget meeting. Last year it might have happened in April and this year it might have happened in March. So on the size of our balance sheet, I mean of our P&L, a INR 1 crore difference here and there makes a difference in the percentage. But structurally there is no increase in our cost structure beyond the normal inflation.

  7. Question

    Gautami Agarwal: Okay, okay sir. Got it, fair. My next question is on the guidance end. So previously our guidance had been of 12% to 14% on the top line and 100 to 150 basis points on the EBITDA margin level. Where I see that this year has been a one-off year and since our growth has been exceptionally well compared to the IPM data, so is it fair to assume that we will be sticking to the earlier guidance going forward?

    Answer, amrut medhekar

    Amrut Medhekar: Good, good. We had given the guidance, ma'am, if you remember last quarter also, we had clearly mentioned and we repeat it at the cost of repetition, we are certainly targeting a 1.5x of the pharma industry growth. Currently the pharma industry is trending anywhere between 6%- 7% to 8%-9%. So this is the window in which it is operating. And if I calculate 1.5x of that, it translates to anywhere between 12% to 15% right now. Page 8 of 17 Jagsonpal Pharmaceuticals Limited April 28, 2026 As the scenario moves forward because now you have some glut of launches into metabolic, anti-obesity and things like that, obviously the market is also expected. I'm repeating the word and underlining this word, expected to perform better.

    Answer, amrut medhekar

    We are saying even if we are not present in anti-obesity right now, our portfolio is strong enough to still beat the market and deliver a 1.5x the growth.

  8. Question

    Sajal Kapoor: Yes, hi. Thank you for the opportunity. Hi team. A few questions from my side. If we track the next two quarters, what quantitative thresholds, I mean for example MR productivity growth or volume growth, would kind of validate that this turnaround that we have reported in Q4 is on track versus slipping back to the industry level growth? Any few, maybe two quantitative thresholds that we can actively monitor.

    Answer, amrut medhekar

    Amrut Medhekar: Hi Sajal, very good afternoon to you. This is Amrut Medhekar. Am I audible?

  9. Question

    Sajal Kapoor: Hi Amrut, yes, you are audible. Thank you.

    Answer, amrut medhekar

    Amrut Medhekar: Yes. So Sajal, if you look at the last reported numbers of Pharmarack, that is what we look at, or IQVIA also, almost similar numbers for the industry. I'll just break it down for you. So volume has been almost flat for the pharma industry on a moving annual total basis. So yearly the volumes have been almost flat. It ranges anywhere between 0.5% to 1.2%-1.3% on a month-on- month basis. The new product contribution is upward of 3%.

    Answer, amrut medhekar

    The price growth is roughly around 5% plus. And therefore the annualized growth is roughly in the range of 7% to 9% month-on-month. Now if you look at the JPL, which is Jagsonpal numbers, and look at Pharmarack data only and try to mirror this, our volume growth is reflected as 2% there. Our new product is matching the industry growth which is 3% plus. Our price growth is little shade higher, which is at around 6.5% to 7% on the price side. So overall our reflection is showing as 12%. So this is where the industry and Jagsonpal is as far as the external reflections are concerned.

    Answer, amrut medhekar

    Internally we are certainly trying to beat these numbers also, Sajal. And I think I had indicated to you on the same questions last quarter as well, that we foresee in the -- as you asked specifically for the next two quarters, I see same numbers getting even better.

  10. Question

    Sajal Kapoor: No, definitely we certainly hope for that, Amrut. And thank you for answering that. Next question is, I mean, so our top 10 brands today contribute about 58%-60% of revenue, our top 10.And these have driven the recent recovery obviously. So over the next two-three quarters, what specific indicators, I mean such as growth contribution from the next 10 brands so to speak, new product revenue share, or reduction in top brand dependency should be tracked to assess, whether growth is broad -- broad-based rather than concentrated? Page 9 of 17 Jagsonpal Pharmaceuticals Limited April 28, 2026 I mean, at what point would you consider the portfolio sufficiently diversified to sustain th

    Answer, amrut medhekar

    Amrut Medhekar: Yes, yes. So Sajal, this is industry-wide I think a very common question which comes across. See, most of the industry and especially the old organization will have this legacy impact. So you will have some brands which are very old but constituting a very large chunk of your top line. And hence it becomes very, very important for you to trend your line when you grow in your growth trajectory, that line has to be kind of managed very well. That you are not threatening your core brand, the volumes to remain or rather grow, so that's your core engine, right? That's going to funnel your growth or fund your growth, future growth.

    Answer, amrut medhekar

    While new products will obviously accelerate that growth. So our focus will continue to be on our power brands, our core brands, which are kind of two or three brands each of the business unit or vertical, therapy vertical that we operate with. That's where our majority of the resources will be deployed. At the same time we are trying to build a portfolio which is future growth proof. Meaning some of the products where we see next 10 years, 20 years growth. These are the products in which we have identified which are complementing our strength and which possibly will have much better chance of success, Sajal. So as I rightly I think put the numbers to you, we are certainly looking at upward of 3% growth coming purely from these strong new product launches as well, while ensuring that our volume and price growth matches or betters the pharma industry.

Show 15 more questions
  1. Question

    Sajal Kapoor: And that's helpful, Amrut. And lastly, we still off the view that the trade generics is not a competition as far as our business is concerned and this lack of volume which is an industry- wide phenomenon, it may or may not be partially if not fully linked to the trade generics growth, but that has nothing to do with any challenges that we see as on today?

    Answer, amrut medhekar

    Amrut Medhekar: Currently none, because this is not a new phenomenon Sajal. This is going on for almost a decade and last five years possibly it got little accelerated post-COVID scenario, wherein the generics had taken a front seat because of lot of Jan Aushadhi Kendras coming up as well as generic businesses of the large pharma companies are also trying to take away the market share. But none of these numbers are currently validated, Sajal. There is no custom report which is available saying that generics is eating into the branded formulation. Right? So I am very sure the way we are operating today, we are able to drive volume growth. We are able to make new product success.

    Answer, amrut medhekar

    And we are also able to take premiumized pricing. So that also talks about our brand strength in clinic with the doctor's mind.

  2. Question

    Avnish Parman: Yes, hi. Good afternoon. Thanks for taking my question. I just had a question about the potential impact of whatever is happening in the Middle East. If you can just outline whatever impact the business is facing and also if you can just touch upon, I guess that all your manufacturing is Page 10 of 17 Jagsonpal Pharmaceuticals Limited April 28, 2026 outsourced. So are you having any kind of feedback from your CMO partners in terms of constraint on raw material supplies, be it API or solvents or packaging material?

    Answer, manish gupta

    Manish Gupta: Yes. So I'll respond to it in two parts. Clearly from a demand perspective, there is no impact of whatever is happening on the Middle East. Okay. So the demand remains secular as far as the industry is concerned. Having said that, clearly there are certain pressures on the cost front, especially packaging material. Clearly all the vendors are seeing cost increases and they obviously while they are carrying certain inventories, they will be looking to pass on some of the cost increases.

    Answer, manish gupta

    Finally I think all of us will find an equilibrium. Having said that, I believe pharmaceutical industry overall will be lesser impacted given that the gross margins in this industry are better than most other industries. So with 65% to 80% gross margins that most of the branded companies enjoy, I think our ability to take some of these cost increases are far superior and we are also allowed a 10% price increase. So some of it will get consumed within that price increase. So all in all, yes, there will be cost impact. Will it have any impact or any significant impact on the profitability of the company? I don't believe so.

  3. Question

    Avnish Parman: Okay, thanks Manish. Just a follow-up on that. Hypothetically speaking, let's say the API cost increases by let's say 50% for the CMO manufacturer. I just wanted to have a sense on how the contracts are structured. Is all of that cost increase passed on to the marketing company or it's like a share of the pain kind of a system where some pain is shared by the CMO guys and some only a part of the pain is passed on to the marketing company? How is it structured usually in the contract?

    Answer, amrut medhekar

    Amrut Medhekar: Thanks for this question. I'm sure you would know that I also have a little bit of CMO background, I actually worked in the CMO earlier on. So typically the cost doesn't get as is transferred to a buyer or a client. So depending on the structure of the agreement, it is typically absorbed over a period of time and in a staggered fashion as per your purchase orders. Because you even your purchase orders are not there for every 15 days or every week. Your purchase orders are also staggered over a quarter. And therefore the absorption is also real-time as per the prices prevailing at that particular point of time when the purchase order is getting released.

    Answer, amrut medhekar

    And while we have an agreement which is longer term in nature, the agreement also allows you time to absorb those increases over quarters. So it's not one quarter impact at all.

  4. Question

    Avnish Parman: No, no. That's fine, I understand. My question was that over time, is it completely passed on to the marketing company which then passes on to the market by price increases or some is absorbed by the CMO guy?

    Answer, amrut medhekar

    Amrut Medhekar: I mean, even the price increases are normally not seen being permanent. They will also fall when the scaledown also happens for those molecules and the supply chains typically kind of smoothens out. So today what we are looking at supply chain constraints is less related to Page 11 of 17 Jagsonpal Pharmaceuticals Limited April 28, 2026 movement of the products, more related to the insurance cost. So typically those will also drop down.

    Answer, manish gupta

    Manish Gupta: See, just to further add on this, finally nobody will do business at a loss. Right? So we have to find a middle ground between the CMO and us and also a middle ground between us and our customers. Okay. So everyone tries to absorb what they can, everyone will pass on what they can, and a new equilibrium gets established. Okay. But having said that, as I was mentioning, the overall cost in our scheme of things is not that significant as it is for many other industries.

  5. Question

    Avnish Parman: Yes, understood. Last question from my side. You mentioned three of your dominant therapies Gynaec, Ortho and Derma. If you see in the last three-four months IPM growth has kind of picked at about close to let’s, say 10%-11%. If you take a blended growth for these three strong therapies of yours, are these therapies on a blended basis going higher than IPM or lower than IPM?

    Answer, amrut medhekar

    Amrut Medhekar: No, they are in line with the IPM growth currently.

  6. Question

    Madhur Rathi: So Mr. Gupta, I'm trying to understand that what percentage of our revenue is coming from e- pharmacies, that is the online Netmeds and 1mg etc., and what are the terms of trades in terms of credit period, working capital as well as margins? Are they higher or lower versus the traditional our sales channel?

    Answer, manish gupta

    Manish Gupta: I'm sorry, I didn't get your name please. Can you repeat?

  7. Question

    And also when last did we take a price hike across our product portfolio and what was the quantum of the price hike? And what is the average salary hike that we are looking on account of our MRs this year?

    Answer, amrut medhekar

    Amrut Medhekar: Madhur sir, in terms of exact percentage I won't be able to share this because we are yet to close our appraisal cycles and KPI completions for the last FY. We are in that process and while we conclude this, it will possibly be this quarter. Second part of your question was that when the price increases will happen. So price increases will be SKU based because as per 12 month, complete 12 month period gets over, then only one SKU is allowed for a price increase. And that's when we actually take as well. It all depends on how much inventory you have with you and how much is the need for the extra inventory to create a purchase order or to trigger a purchase order.

  8. Question

    Madhur Rathi: Right. And sir just a final question. Sir, if I look at our scale versus the size of the market, it's much larger in terms of I think SKU offerings as well. Sir, so our growth estimates of 1.5 times the market, are we being conservative in that in either new product addition or growing in these three segments Gynaec, Ortho and Dermatology? So either in new product addition are we being conservative because our scale is not what is the market, our scale is not that high?

    Answer, amrut medhekar

    Amrut Medhekar: I'm not able to hear you clearly, but I can possibly sense what you wanted to ask. I'll just answer that. See, our market as you said, I think Manish ji has already elaborated those numbers to you. One is the earlier question which you asked about the price increase, our 92% of the portfolio is outside the NLEM, which is price control. So almost you can say 90% of my portfolio I can go up to a price increase of 9.9%. Second part that you asked the question is whether our participated market or covered market is big enough to drive our growth upward of 1.5x. Is my question understood correctly?

  9. Question

    Madhur Rathi: Yes sir, and also on the new product addition because versus the target market our product addition can be much faster, so yes.

    Answer, amrut medhekar

    Amrut Medhekar: Yes, correct. So we are trying to rejuvenate that. As I mentioned in my opening remarks as well, we are trying to rejuvenate our portfolio but obviously we are working with a specialty segment where prescription pickup doesn't happen from day one. New product establishment is a very, very hard work for prescriptions to start flowing in from each and every pin code of the country, which will take possibly a year plus for us to do that. And that's what we are working out with new product addition. As I mentioned, as per Pharmarack, we are matching or doing better than the pharma industry in terms of our new product performance. So we are already at 3% plus in terms of our growth contribution from the new products.

    Answer, amrut medhekar

    And we are trying to further accelerate that.

  10. Question

    Aditya Chheda: Hi, good afternoon. Can you break your Q4 FY26 and FY26 growth in price, volume and new products?

    Answer, amrut medhekar

    Amrut Medhekar: Yes, I'll give you the breakup for Q4 which you are asking. So for us volume growth was almost in line with the market. I'll give you first the Pharmarack numbers how they are reflected for -- unfortunately I don't have the quarter right now, I have the year. So can I give you for the year right now?

  11. Question

    Aditya Chheda: Yes, that is fine.

    Answer, amrut medhekar

    Amrut Medhekar: So I had given it earlier, I repeat. So for the Indian Pharma Market, the volume growth has been approximately 1%, little less than 1%. New product has been little higher than 3%, it was around 3.1%. And price is little less than 5%, so it was around 4.8%. So sum total of this is around 8.5%. If you round it off, it will become 9%. Now for Jagsonpal, the numbers reported are volume growth is 2%.

    Answer, amrut medhekar

    New product is matching which is 3.2%. And our price growth is in the range of 6% to 7%. Sum total of this comes to 12%.

  12. Question

    Hitaindra Pradhan: Hi sir, I hope I'm audible. Sorry, I missed this like -- about new product pipelines, which therapeutics you said those molecules would be?

    Answer, amrut medhekar

    Amrut Medhekar: Yes, our molecules you will possibly come to know in a month's time, but we are looking at some good breakthrough molecules and hopefully we'll be in the second wave of launch for this first-in-India product. So we are preparing ourselves for Gynaecology one therapy, second obviously we are looking at Ortho and Derma. So you will come to know about this, we'll make an announcement at the opportuned time, mostly either May end or June first week.

  13. Question

    Hitaindra Pradhan: Got it. And that would have any implications on our incremental cost, margins or working capital, all these initiatives?

    Answer, manish gupta

    Manish Gupta: No, not at all. I mean, any implications on our operating cost and or working capital? No. See, as you would have noticed, we are already working on a very lean working capital, 11 days, and this has been consistent for two years now. So we believe we are best-in-class as far as working capital management is concerned and we intend to stay that way.

  14. Question

    Anupam Agarwal: Yes, I'm asking the top 10 brands which contribute 58% to your revenue, what was growth in those 10 brands and what was the growth in the balance 42% of the business?

    Answer, amrut medhekar

    Amrut Medhekar: It's almost in line. So top 10 brands are obviously constituting much more healthier bottom line for us, so our growth on those brands has been in line with the rest of the portfolio. It's hardly 1% change. But I think we'll arrive at the right number because we have not added the numbers and seen it, we'll come back, but it won't be very, very different.

  15. Question

    Anupam Agarwal: Got it. Sir, last question if I may. Can you quantify in absolute figure what is the MR productivity for each of these three business segments?

    Answer, amrut medhekar

    Amrut Medhekar: I won't be able to give you exact numbers there for each of these businesses in terms of productivity. However, I can promise you one thing that the growth will be entirely driven with the productivity improvement as we don't intend to increase the MR numbers currently or managers number currently. So manpower remaining same, our growth will be still higher than the IPM. Anupam Agarwal: Can you rank them in what is highest in terms of MR productivity between one, two, three?

Questions about this call

When was the Jagsonpal Pharmaceuticals Q4 FY26 earnings call transcript filed?
Jagsonpal Pharmaceuticals filed the transcript with the exchange on 4 May 2026. This page is built from that transcript.
What does this page list?
39 statements from the transcript across 8 topics, 24 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 25 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Jagsonpal Pharmaceuticals Q4 FY26 concall: Jagsonpal Pharmaceuticals Limited's objective is to beat Indian Pharma Market growth, with an aspiration to beat it by 1.5x · DalalOS